A postmarketing surveillance study of the safety and efficacy of ReFacto® (St Louis-derived active substance) in patients with haemophilia A

Haemophilia

Volumn 11, Issue 5, 2005, Pages 444-451

  Smith, Mark P ^a   Giangrande, P ^b   Pollman, H ^c   Littlewood, R ^d   Kollmer, C ^d   Feingold, J ^d  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c Raphaels Klinik Munster GmbH   (Germany)

^d PFIZER INC   (United States)

Author keywords

Factor VIII; Haemophilia A; On demand treatment; Prophylaxis treatment; Surgical prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BACKACHE; BLEEDING DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG MARKETING; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTIVE SURGERY; GASTROENTERITIS; HEART MUSCLE ISCHEMIA; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE BLEEDING; OPEN STUDY; PHLEBITIS; PHYSICIAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS, SURGICAL; HUMANS; INFANT; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS;

EID: 24644500661     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01131.x     Document Type: Article

References (39)

1. Tuddenham EG, Trabold NC, Collins JA, Hoyer LW. The properties of factor VIII coagulant activity prepared by immunoadsorbent chromatography. J Lab Clin Med 1979; 93: 40-53.
2. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
3. White GC, Courter S, Bray GL, Lee M, Gomperts ED, the Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
4. Azzi A, De Santis R, Morfini M et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001; 98: 2571-3.
5. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D, the Kogenate Study Group. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of hemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
6. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38 (2 Suppl. 4): 44-51.
7. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (95 kD) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 5939-42.
8. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the ReFacto Phase III Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
9. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38 (2 Suppl. 4): 52-9.
10. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 860.
11. Giangrande PL, Bayer Study Group. Safety and efficacy of Kogenate(R) Bayer in previously untreated patients (PUPs) and minimally treated patients (MTP). Haemophilia 2002; 8: 19-22.
12. Schwarts RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-5.
13. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000; 83: 811-6.
14. Tarantino MD, Collins PW, Hay CRM et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia. Haemophilia 2004; 10: 428-37.
15. Lusher JM, Salzman PM. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group. Semin Hematol 1990; 27: 1-7.
16. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P, the ReFacto-AICE Study Group. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126: 398-404.
17. Stieltjes N, Altisent C, Auerswald G et al. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia 2004; 10: 1-7.
18. Sukhu K, Harrison P, Keeling D. Factor VIII assays in haemophilia A patients treated with Refacto. Br J Haematol 2003; 121: 379-80.
19. Pollmann H, Richter H, Siegmund B. Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A. Haemophilia 2004; 10: 676.
20. Hanrahan J, McKinnell J, Storrs B et al. Successful use of B-domain deleted factor VIII for resection of pituitary adenoma in a paediatric patient with severe haemophilia A. Haemophilia 2003; 9: 650.
21. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
22. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Meta-analysis of observational studies of full-length and B-domain deleted factor VIII for prophylaxis - a standard statistical approach. Haemophilia 2003; 9: 748-50.
23. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII for prophylaxis - a robust meta-analytic finding. Haemophilia 2004; 10: 449-51.
24. Brown SA, Yee TT, Griffioen A, Lee C. Comparative study of full-length and B-domain deleted factor VIII concentrates. Haemophilia 2003; 9: 745.
25. Mikaelsson M. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal. Haemophilia 2004; 10: 305-7.
26. Lee ML, Morfini M. Controversial use of meta-analysis for factor VIII pharmacokinetic data. Haemophilia 2003; 9: 746-7.
27. Van der Bom JG, Fischer K, van den Berg HM. Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis. Haemophilia 2003; 9: 744.
28. Biggs R. Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol 1974; 26: 313-29.
29. Brinkhous KM, Roberts HR, Weiss A. Prevalence of inhibitors in hemophilia A and B. Thromb Diath Haemorrh 1972; (Suppl. 51): 315-21.
30. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-29.
31. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study: II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
32. DiMichele DM, Aledort LM. Inhibitor development with post-licensure use of recombinant factor VIII (rFVIII): the US hemophilia region II experience. Thromb Haemost 1997; (Suppl.): 87.
33. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8 (Suppl. 2): 23-9.
34. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
35. Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550 (Letter).
36. de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, de Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
37. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J. Inhibitors in factor VIII deficient hemophilia: comparison of frequency based upon treatment product. Blood 1992; 80: 231A.
38. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. Thromb Haemost 2004; 2: 574-83.
39. Kreuz W, Ettingshausen CE, Zyschka A et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma derived and recombinant products. Semin Thromb Hemost 2002; 28: 285-90.